1. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug

   • Esther F. A. Brandon
   • Rolf W. Sparidans
   • Jan H. M. Schellens

   OriginalPaper 13 January 2006 Pages: 3 - 14

2. The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro

   • Dragana Janković
   • Milica Pesić
   • Sabera Ruždijić

   OriginalPaper 13 January 2006 Pages: 15 - 25

3. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas

   • H. W. M. van Laarhoven
   • G. Gambarota
   • C. J. A. Punt

   OriginalPaper 13 January 2006 Pages: 27 - 36

4. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates

   • Jackie Walling

   ReviewPaper 13 January 2006 Pages: 37 - 77

5. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis

   • Agustin A. Garcia
   • Syma Iqbal
   • Jeff Weber

   OriginalPaper 13 January 2006 Pages: 79 - 83

6. Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

   • Jacqueline Vuky
   • Christina Isacson
   • Andrew Jacobs

   OriginalPaper 13 January 2006 Pages: 85 - 88

7. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma

   • Karl D. Lewis
   • John A. Thompson
   • Rene Gonzalez

   OriginalPaper 13 January 2006 Pages: 89 - 94